Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis

Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis - Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022873

Enrollment

Registered

2016-07-01

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glomerulonephritis

Interventions

denosumab 60mg subcutaneously once in 6 months alendronate sodium 35mg orally every week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with glomerulonephritis planned to be treated with steroid for over 6 months in our hospital.

Exclusion criteria

Exclusion criteria: 1.Cases where no consent is obtained. 2.Patients allergic to alendronate sodium or denosumab. 3.Patients pregnant or potential. 4.Other cases where physicians regard as inappropriate.

Design outcomes

Primary

Measure	Time frame
change of bone mineral density	—

Secondary

Measure	Time frame
change of bone turnover markers, proteinuria, kidney function	—

Countries

Japan

Contacts

Public ContactKei saitoh

Kakogawa central city hospital department of Nephrology and kidney center

kei.saitoh0705@gmail.com0794323531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026